<DOC>
	<DOCNO>NCT00416598</DOCNO>
	<brief_summary>This phase II trial study side effect well decitabine work give maintenance therapy standard therapy treat patient previously untreated acute myeloid leukemia . Drugs use chemotherapy , cytarabine , daunorubicin , etoposide , busulfan , decitabine , work different way stop growth cancer cell , either kill cell stop divide . Giving decitabine maintenance therapy standard therapy may keep cancer cell come back .</brief_summary>
	<brief_title>Decitabine Maintenance Therapy After Standard Therapy Treating Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine efficacy , feasibility , toxicity one year maintenance therapy decitabine give patient &lt; 60 year untreated acute myeloid leukemia ( AML ) achieve maintain first complete remission ( CR ) follow establish induction intensification regimen . II . To determine 1-year disease free survival rate AML patient first CR treat maintenance decitabine . SECONDARY OBJECTIVES : I . To measure biologic response decitabine evaluable patient fusion gene determine eradication minimal residual disease . II . To measure surrogate deoxyribonucleic acid ( DNA ) demethylation include downregulation DNA methyltransferase 1 ( DNMT1 ) induction fetal hemoglobin . III . To examine significance gene expression follow ex vivo decitabine exposure primary AML cell take time diagnosis clinical outcome gene expression time relapse vivo decitabine exposure . IV . To continue evaluate effectiveness cytogenetically risk-adapted approach consolidation therapy patient core bind factor ( CBF ) non-CBF AML . V. To continue investigation begin Cancer Leukemia Group B ( CALGB ) 19808 aim correlation rate relapse toxicity intravenous ( IV ) busulfan pharmacokinetics busulfan etoposide use preparative regimen autologous stem cell transplantation AML patient first CR . VI . To correlate outcome measure complete response ( CR ) , disease-free survival ( DFS ) , event-free survival ( EFS ) , overall survival ( OS ) , pretreatment characteristic age , sex , race , blood count , morphology , immunophenotype , cytogenetics , molecular feature AML . OUTLINE : REMISSION INDUCTION THERAPY : Patients receive cytarabine IV 168 hour day 1-7 daunorubicin hydrochloride IV 5-10 minute etoposide IV 2 hour day 1-3 . Patients undergo bone marrow biopsy day 14 . Patients residual leukemia proceed second remission induction therapy . Patients achieve complete remission ( CR ) proceed intensification therapy . SECOND REMISSION INDUCTION THERAPY : Patients receive cytarabine IV 120 hour day 1-5 daunorubicin hydrochloride IV etoposide IV 2 hour day 1 2 . Patients undergo bone marrow biopsy day 42 . Patients residual leukemia remove study . Patients achieve CR proceed intensification therapy . INTENSIFICATION THERAPY : Patients stratify receive intensification therapy accord cytogenetic finding ( favorable cytogenetics [ ( 8 ; 21 ) ( q22q22 ) , inv ( 16 ) ( p13 ; q22 ) , ( 16 ; 16 ) ( p13 ; q22 ) cytogenetic and/or molecular analysis ] v unfavorable cytogenetics [ cytogenetic finding , include normal cytogenetics ] ) . FAVORABLE CYTOGENETICS : Within 2-4 week achieve CR , patient receive high-dose cytarabine IV 3 hour twice daily day 1 , 3 , 5 . Treatment repeat every 28 day 3 course . UNFAVORABLE CYTOGENETICS : Peripheral blood stem cell ( PBSC ) mobilization : Within 2-4 week achieve CR , patient receive etoposide IV 96 hour high-dose cytarabine IV 2 hour twice daily day 1-4 filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 14 continue blood count recover . Patients proceed transplantation . PBSC OR BONE MARROW TRANSPLANTATION : Patients receive busulfan IV 2 hour 4 time daily day -7 -4 etoposide IV 4 hour day -3 . Patients undergo autologous PBSC bone marrow transplantation day 0 receive G-CSF SC daily begin day 0 continue blood count recover . UNFAVORABLE CYTOGENETICS AND UNABLE TO UNDERGO PBSC TRANSPLANTATION : Within 2-4 week achieve CR , patient receive etoposide , high-dose cytarabine , G-CSF unfavorable cytogenetics ( PBSC mobilization ) follow 2 course high-dose cytarabine favorable genetics . MAINTENANCE THERAPY : Within 60-90 day completion intensification therapy , patient receive decitabine IV 1 hour day 1-5 . Treatment repeat every 6 week 8 course . After completion study treatment , patient follow every 2 month 1 year , every 6 month 2 year , yearly 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Unequivocal histologic diagnosis AML ( &gt; 20 % blast bone marrow base World Health Organization [ WHO ] and/or French American British [ FAB ] classification ) , exclude M3 ( acute promyelocytic leukemia ) ; patient antecedent myelodysplasia eligible treatment trial bone marrow biopsy show myelodysplastic syndrome ( MDS ) &gt; 3 month prior enrollment ; patient therapyrelated AML eligible free primary disease receive chemotherapy least 2 year No prior 5azacitidine decitabine therapy No prior treatment leukemia myelodysplastic syndrome four permissible exception : Emergency leukapheresis Emergency treatment hyperleukocytosis hydroxyurea Cranial radiation therapy ( RT ) central nervous system ( CNS ) leukostasis ( one dose ) Growth factor/cytokine support</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>